Lupin (500257) Q3 24/25 earnings summary

Executive summary

• Achieved double-digit revenue and profit growth, with EBITDA margins at a five-year high of 24.3% for Q3 FY25 and 24% for the nine-month period, reflecting strong operational performance.

• India and North America each grew 12% year-over-year, EMEA rose 21%, while Emerging Markets declined 5% year-over-year.

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, were approved by the Board on February 11, 2025.

• Margins improved despite increased R&D investments, with guidance to maintain margins in the 22%-23.5% range for FY25.

• Statutory auditors conducted a limited review and found no material misstatements in the financial disclosures.

Financial highlights

• Q3 FY25 sales: INR 56,186 mn, up 10.6% year-over-year; nine-month sales: INR 166,299 mn, up 12.7% year-over-year.

• Consolidated revenue from operations for Q3 FY25 was ₹57,677.1 million, up from ₹51,974.1 million in Q3 FY24; nine-month revenue was ₹170,407.7 million, up from ₹150,500.3 million year-over-year.

• Net income for Q3 FY25 increased 39.5% year-over-year to INR 8,552 mn; gross profit margin improved to 69.4%.

• EBITDA for Q3 FY25 was INR 13,659 mn (24.3% margin), up 33.7% year-over-year.

• Net debt reduced to INR 103 crores from INR 477 crores as of March 2024; net debt/equity ratio at 0.01 in Q3 FY25.

Outlook and guidance

• Expect to maintain EBITDA margins in the 23%-23.5% range for FY25.

• Focus on complex generics, biosimilars, and innovative product launches in regulated markets by 2028.

• R&D spend projected at INR 1,750-1,800 crores for FY25, with a significant increase in Q4.

• The company continues to focus on operational efficiency and resolving ongoing disputes to avoid litigation costs and uncertainties.